uniQure rockets on map to market for Huntington's therapy
Crucially for the Netherlands-based biopharma company, the FDA has said that the composite Unified Huntington's Disease Rating Scale (cUHDRS) can serve as an intermediate clinical endpoint for its review, along with the use of neurofilament light chain (NfL) levels in cerebrospinal fluid (CSF) as a biomarker for efficacy.
UniQure Clears Path to Accelerated Approval for Huntington’s Gene Therapy
In a Type B meeting, the FDA signified that it will allow uniQure to use a natural history control, the composite Unified Huntington’s Disease Rating Scale, and neurofilament light chain levels to support the accelerated approval of its gene therapy AMT-130.
Hosted on MSN2d
uniQure Stock Hits 18-Month High After FDA Agreement Clears Pathway For Huntington’s Treatment: Retail Gets More OptimisticShares of gene therapy company uniQure more than doubled on Tuesday before trimming some gains, reaching their highest levels ...
Qure's AMT-130 shows promising results for Huntington’s disease. Learn why QURE stock faces commercialization challenges ...
Investor's Business Daily on MSN1d
UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's DrugUniQure stock doubled Tuesday after the company reached a testing agreement with the FDA for its Huntington's disease ...
Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on uniQure (QURE – Research Report). The associated price target ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback